This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ioannides, C. G. Articles by Freedman, R. S. Search for Related Content PubMed PubMed Citation Articles by Ioannides, C. G. Articles by Freedman, R. S.

Tumor Cytolysis by Lymphocytes Infiltrating Ovarian Malignant Ascites¹

Departments of Gynecology [C. G. I., S. R., J. T. W., C. L. E., R. S. F.] and Immunology [C. D. P.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Tumor-associated lymphocytes (TAL) were isolated from the ascitic fluid of patients with adenocarcinoma of the ovary. These cells proliferated and expanded by 100–600-fold as either CD3⁺ CD4⁺ or Cd3⁺ CD8⁺ cultures in the presence of moderate concentrations (50–200 cetus units/ml) of recombinant interleukin 2 and reached high numbers (5 x 10⁸-1 x 10⁹). After expansion of 16 TAL samples from 15 patients, 5 of the 7 isolated ovarian cytotoxic T-lymphocyte cell lines of T-cell receptor (TCR) (ß)⁺ CD3⁺ CD8⁺ CD4^- phenotype exhibited preferential cytolytic activity against autologous tumor targets and significantly lower cytolytic activity against allogeneic tumor targets and the natural killer-sensitive cell line K562.

The cytolytic activity of the CD8⁺ TAL was inhibited by operationally anti-TCR (ß) monoclonal antibody and monoclonal antibody specific for the CD3 differentiation antigen, indicating that the TCR and CD3 are involved in the cytolytic process. The other TAL cultures demonstrated similar cytolytic activity against both autologous and allogeneic tumors. The phenotype of these TAL was predominantly TCR (ß)⁺ CD3⁺ CD4⁺ CD8^-. Certain CD3⁺ CD8⁺ T-cell clones isolated from representative TAL exhibited preferential autologous tumor-specific cytotoxicity that may be major histocompatibility complex restricted. Other CD3⁺ CD8⁺ and CD3⁺ CD4⁺ clones exhibited nonmajor histocompatibility complex restricted cytotoxicity. These results demonstrate that CD3⁺ CD4⁺ and CD3⁺ CD8⁺ T-cells present in the ovarian malignant ascites can be propagated in large numbers and for long time intervals as T-cell lines in vitro. This finding may be significant for further investigation of ovarian tumor-specific cytotoxic T-lymphocytes and future adoptive specific immunotherapy studies.

¹ Supported in part by New Program Development Funds (J. T. W., C. G. I.), Texas Higher Coordinating Board Advanced Technology Program Grant 000015-049 (R. S. F., C. G. I.), and NIH Grant RR-5511 (C. G. I.).

² To whom all requests for reprints should be addressed, at Department of Gynecology, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 67, Houston, TX 77030.

Received 7/ 2/90. Accepted 5/24/91.

This article has been cited by other articles:

				S. Madhusudan, A. Tamir, N. Bates, E. Flanagan, M. E. Gore, D. P. J. Barton, P. Harper, M. Seckl, H. Thomas, N. R. Lemoine, et al. A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene Clin. Cancer Res., May 1, 2004; 10(9): 2986 - 2996. [Abstract] [Full Text] [PDF]

				C. L. Efferson, J. Schickli, B. K. Ko, K. Kawano, S. Mouzi, P. Palese, A. Garcia-Sastre, and C. G. Ioannides Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene J. Virol., July 1, 2003; 77(13): 7411 - 7424. [Abstract] [Full Text] [PDF]

				B. W. Anderson, G. E. Peoples, J. L. Murray, M. A. Gillogly, D. M. Gershenson, and C. G. Ioannides Peptide Priming of Cytolytic Activity to HER-2 Epitope 369-377 in Healthy Individuals Clin. Cancer Res., November 1, 2000; 6(11): 4192 - 4200. [Abstract] [Full Text] [PDF]

				R. S. Freedman, A. P. Kudelka, J. J. Kavanagh, C. Verschraegen, C. L. Edwards, M. Nash, L. Levy, E. N. Atkinson, H.-Z. Zhang, B. Melichar, et al. Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon-{{gamma}} and Recombinant Interleukin 2 with or without Tumor-infiltrating Lymphocytes in Patients with Ovarian or Peritoneal Carcinoma Clin. Cancer Res., June 1, 2000; 6(6): 2268 - 2278. [Abstract] [Full Text]

				A. E. Loercher, M. A. Nash, J. J. Kavanagh, C. D. Platsoucas, and R. S. Freedman Identification of an IL-10-Producing HLA-DR-Negative Monocyte Subset in the Malignant Ascites of Patients with Ovarian Carcinoma That Inhibits Cytokine Protein Expression and Proliferation of Autologous T Cells J. Immunol., December 1, 1999; 163(11): 6251 - 6260. [Abstract] [Full Text] [PDF]

				Y. Rongcun, F. Salazar-Onfray, J. Charo, K.-J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, et al. Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas J. Immunol., July 15, 1999; 163(2): 1037 - 1044. [Abstract] [Full Text] [PDF]

				G. Strau{beta}, B. Guckel, D. Wallwiener, and G. Moldenhauer Without Prior Stimulation, Tumor-associated Lymphocytes from Malignant Effusions Lyse Autologous Tumor Cells in the Presence of Bispecific Antibody HEA125xOKT3 Clin. Cancer Res., January 1, 1999; 5(1): 171 - 180. [Abstract] [Full Text] [PDF]